NCT02230449

Brief Summary

The aim of the study is to analyze the expression of genes and microRNAs potentially involved in oocyte competence in follicles of different sizes (\<17mm and ≥17mm) at the time of oocyte pick-up.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2014

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2014

Completed
18 days until next milestone

First Submitted

Initial submission to the registry

August 19, 2014

Completed
15 days until next milestone

First Posted

Study publicly available on registry

September 3, 2014

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2016

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2016

Completed
Last Updated

September 5, 2017

Status Verified

September 1, 2017

Enrollment Period

1.8 years

First QC Date

August 19, 2014

Last Update Submit

September 1, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Cumulus cell RNA expression correlation with blastocyst formation potential and quality

    At the day of oocyte pick-up, cumulus cells will be collected from each cumulus oocyte complex. RNA extraction will be performed from those cumulus cells and expression levels of 5 genes and 1 miRNA will be measured (compared with that of a housekeeping gene). Oocytes of those samples will be injected and cultured with routine Assisted Reproduction Techniques. At the day 5 \& 6, after the oocyte pick-up procedure, each blastocyst formed will be noted and the quality of each blastocyst will be recorded. The blastocyst grading will be done according to Gardner's blastocyst morphological criteria (degree of expansion of the blastocoele cavity: 1 to 5, inner cell mass morphology: A to C, trophectoderm morphology: A to C). The composite primary outcome measure will allow the correlation of the expression levels of 5 genes and 1 miRNA of each cumulus oocyte complex with the corresponding embryo morphology on day 5 (presence or absence of a blastocyst) and blastocyst quality.

    6 days

Secondary Outcomes (1)

  • Implantation Rate

    2 months

Eligibility Criteria

Age18 Years - 39 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Infertile couples applying to the clinic for assisted reproductive technologies

You may qualify if:

  • No more than 2 previous treatment cycles
  • No history of recurrent spontaneous abortions
  • Age ≤ 39 years
  • BMI \< 30 kg / m2
  • ≥ 8 cumulus-oocyte-complexes (COC) retrieved
  • human Chorionic Gonadotrophin (hCG) triggering

You may not qualify if:

  • Preimplantaion Genetic Diagnosis (PGD) or Preimplantation Genetics Screening (PGS) indication
  • Maximum number of 24 COC during pickup
  • Failure to culture until Day 5
  • Polycystic ovary syndrome
  • Severe endometrial factor that can influence implantation
  • Uterine malformation or congenital anomaly
  • Severe male factor (Azoospermia)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Memorial Sisli Hospital ART Center

Istanbul, 34385, Turkey (Türkiye)

Location

Related Publications (1)

  • Kahraman S, Cetinkaya CP, Cetinkaya M, Tufekci MA, Ekmekci CG, Montag M. Is there a correlation between follicle size and gene expression in cumulus cells and is gene expression an indicator of embryo development? Reprod Biol Endocrinol. 2018 Jul 21;16(1):69. doi: 10.1186/s12958-018-0388-0.

Biospecimen

Retention: SAMPLES WITH DNA

Cumulus cells from each oocyte of every enrolled patient will be collected and mRNA \& miRNA extraction will be performed.

MeSH Terms

Conditions

Infertility

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital Diseases

Study Officials

  • Semra Kahraman, Prof. Dr

    Manager of ART and Genetics Center

    STUDY CHAIR
  • Semra Kahraman, Prof. Dr.

    Manager of ART and Genetics Center

    STUDY DIRECTOR
  • Mehmet Ali Tufekci, PhD

    ART Center Research and Development Department

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of ART and Genetics Center

Study Record Dates

First Submitted

August 19, 2014

First Posted

September 3, 2014

Study Start

August 1, 2014

Primary Completion

June 1, 2016

Study Completion

September 1, 2016

Last Updated

September 5, 2017

Record last verified: 2017-09

Locations